Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct 27;6(1):100949.
doi: 10.1016/j.jhepr.2023.100949. eCollection 2024 Jan.

Opinion paper on the diagnosis and treatment of progressive familial intrahepatic cholestasis

Patrick McKiernan  1 , Jesus Quintero Bernabeu  2 , Muriel Girard  3 , Giuseppe Indolfi  4   5 , Eberhard Lurz  6 , Palak Trivedi  7   8   9
Affiliations

Opinion paper on the diagnosis and treatment of progressive familial intrahepatic cholestasis

Patrick McKiernan et al. JHEP Rep. .

Erratum in

Abstract

Background & aims: Progressive familial intrahepatic cholestasis (PFIC) relates to a group of rare, debilitating, liver disorders which typically present in early childhood, but have also been reported in adults. Without early detection and effective treatment, PFIC can result in end-stage liver disease. The aim of the paper was to put forward recommendations that promote standardisation of the management of PFIC in clinical practice.

Methods: A committee of six specialists came together to discuss the challenges faced by physicians in the management of PFIC. The committee agreed on two key areas where expert guidance is required to optimise care: (1) how to diagnose and treat patients with a clinical presentation of PFIC in the absence of clear genetic test results/whilst awaiting results, and (2) how to monitor disease progression and response to treatment. A systematic literature review was undertaken to contextualise and inform the recommendations.

Results: An algorithm was developed for the diagnosis and treatment of children with suspected PFIC. The algorithm recommends the use of licensed inhibitors of ileal bile acid transporters as the first-line treatment for patients with PFIC and suggests that genetic testing be used to confirm genotype whilst treatment is initiated in patients in whom PFIC is suspected. The authors recommend referring patients to an experienced centre, and ensuring that monitoring includes measurements of pruritus, serum bile acid levels, growth, and quality of life following diagnosis and during treatment.

Conclusions: The algorithm presented within this paper offers guidance to optimise the management of paediatric PFIC. The authors hope that these recommendations will help to standardise the management of PFIC in the absence of clear clinical guidelines.

Impact and implications: This opinion paper outlines a consistent approach to the contemporaneous diagnosis, monitoring, referral and management of children with progressive familial intrahepatic cholestasis. This should assist physicians given the recent developments in genetic diagnosis and the availability of effective drug therapy. This manuscript will also help to raise awareness of current developments and educate health planners on the place for new drug therapies in progressive familial intrahepatic cholestasis.

Keywords: IBAT inhibitor; PFIC; diagnosis; treatment.

PubMed Disclaimer

Conflict of interest statement

PM: consultant for Albireo Pharma. JQB: consultant for Albireo Pharma, Mirum, Orphalan, Astra-Zeneca and Intercept Pharmaceuticals. MG: consultant for Albireo Pharma, Mirum and Orphalan. GI: consultant for Albireo Pharma, Mirum and Kedrion Pharma. EL: speaker agreements with Albireo Pharma, Mirum, Nutiricia and Takeda. PT: consultant for Albireo Pharma, GSK, Dr Falk Pharma, Gilead Medical, Advanz / Intercept Pharmaceuticals, Pliant Pharma, Cymabay. Grant Support from BMS, GSK, Dr Falk Pharma, Gilead Medical, Advanz / Intercept Pharmaceuticals, Regeneron, the Wellcome Trust, the Medical Research Foundation, LifeArc, Innovate UK and NIHR. Please refer to the accompanying ICMJE disclosure forms for further details.

Figures

None
Graphical abstract
Fig. 1
Fig. 1
Proposed diagnosis and treatment algorithm for patients with unexplained pruritus and/or jaundice in conjunction with elevated SBAs. GGT, gamma-glutamytransferase; IBAT, ileal bile acid transporter; PFIC, progressive familial intrahepatic cholestasis; SBA, serum bile acids; UDCA, ursodeoxycholic acid; USS, ultrasound scan.
See this image and copyright information in PMC

References

    1. Henkel S.A., Squires J.H., Ayers M., et al. Expanding etiology of progressive familial intrahepatic cholestasis. World J Hepatol. 2019;11(5):450–463. - PMC - PubMed
    1. Jones-Hughes T., Campbell J., Crathorne L. Epidemiology and burden of progressive familial intrahepatic cholestasis: a systematic review. Orphanet J Rare Dis. 2021;16(1):255. - PMC - PubMed
    1. Felzen A., Verkade H.J. The spectrum of progressive familial intrahepatic cholestasis disease: update on pathophysiology and emerging treatments. Eur J Med Genet. 2021;64(11) - PubMed
    1. Vitale G., Mattiaccio A., Conti A., et al. Genetics in familial intrahepatic cholestasis: clinical patterns and development of liver and biliary cancers: a review of the literature. Cancers (Basel) 2022;14(14):3421. - PMC - PubMed
    1. Clayton R.J., Iber F.L., Ruebner B.H., et al. Byler disease. Fatal familial intrahepatic cholestasis in an Amish kindred. Am J Dis Child. 1969;117:112–124. - PubMed

LinkOut - more resources